

## SUMMARY OF PRODUCT CHARACTERISTICS

### 1. NAME OF THE MEDICINAL PRODUCT

Kovaltry 250 IU powder and solvent for solution for injection  
Kovaltry 500 IU powder and solvent for solution for injection  
Kovaltry 1000 IU powder and solvent for solution for injection  
Kovaltry 2000 IU powder and solvent for solution for injection

### 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

- Kovaltry 250IU powder and solvent for solution for injection  
Kovaltry contains approximately 250 IU (100 IU / 1 mL) of recombinant human coagulation factor VIII (INN: octocog alfa) after reconstitution
- Kovaltry 500IU powder and solvent for solution for injection  
Kovaltry contains approximately 500 IU (200 IU / 1 mL) of recombinant human coagulation factor VIII (INN: octocog alfa) after reconstitution.
- Kovaltry 1000IU powder and solvent for solution for injection  
Kovaltry contains approximately 1000 IU ( 400 IU / 1 mL) of recombinant human coagulation factor VIII (INN: octocog alfa) after reconstitution .
- Kovaltry 2000IU powder and solvent for solution for injection  
Kovaltry contains approximately 2000 IU (400 IU / 1 mL) of recombinant human coagulation factor VIII (INN: octocog alfa) after reconstitution.

The potency (IU) is determined using the European Pharmacopoeia chromogenic assay. The specific activity of Kovaltry is approximately 4000 IU/mg protein.

Octocog alfa (Full length recombinant human coagulation factor VIII (rDNA)) is a purified protein that has 2,332 amino acids. It is produced by recombinant DNA technology in baby hamster kidney cells (BHK) into which the human factor VIII gene has been introduced. Kovaltry is prepared without the addition of any human or animal derived protein in the cell culture process, purification or final formulation.

For the full list of excipients, see section 6.1.

### 3. PHARMACEUTICAL FORM

Powder and solvent for solution for injection (vial adapter)

Powder: solid, white to slightly yellow.

Solvent: water for injections, a clear solution.

### 4. CLINICAL PARTICULARS

#### 4.1 Therapeutic indications

Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency). Kovaltry can be used for all age groups.

## 4.2 Posology and method of administration

Treatment should be under the supervision of a physician experienced in the treatment of haemophilia.

### Treatment monitoring

During the course of treatment, appropriate determination of factor VIII levels is advised to guide the dose to be administered and the frequency of repeated infusions. Individual patients may vary in their response to factor VIII, demonstrating different half-lives and recoveries. Dose based on bodyweight may require adjustment in underweight or overweight patients.

In the case of major surgical interventions in particular, precise monitoring of the substitution therapy by means of coagulation analysis (plasma factor VIII activity) is indispensable.

### Posology

The dose and duration of the substitution therapy depend on the severity of the factor VIII deficiency, on the location and extent of the bleeding and on the patient's clinical condition.

The number of units of factor VIII administered is expressed in International Units (IU), which are related to the current WHO standard for factor VIII products. Factor VIII activity in plasma is expressed either as a percentage (relative to normal human plasma) or in International Units (relative to an International Standard for factor VIII in plasma).

One International Unit (IU) of factor VIII activity is equivalent to that quantity of factor VIII in one mL of normal human plasma.

### *On Demand Treatment*

The calculation of the required dose of factor VIII is based on the empirical finding that 1 International Unit (IU) factor VIII per kg body weight raises the plasma factor VIII activity by 1.5% to 2.5% of normal activity.

The required dose is determined using the following formulae:

Required units = body weight (kg) x desired factor VIII rise (% or IU/dL) x reciprocal of observed recovery (i.e. 0.5 for recovery of 2.0%).

The amount to be administered and the frequency of administration should always be targeted to the clinical effectiveness required in the individual case.

In the case of the following haemorrhagic events, the factor VIII activity should not fall below the given level (in % of normal) in the corresponding period. The following table can be used to guide dosing in bleeding episodes and surgery:

**Table 1: Guide for dosing in bleeding episodes and surgery**

<b>Degree of haemorrhage/ Type of surgical procedure</b>	<b>Factor VIII level required (%) (IU/dL)</b>	<b>Frequency of doses (hours)/ Duration of therapy (days)</b>
<u>Haemorrhage</u>		
Early haemarthrosis, muscle bleeding or oral bleeding	20 – 40	Repeat every 12 to 24 hours. At least 1 day, until the bleeding episode as indicated by pain is resolved or healing is achieved.
More extensive haemarthrosis, muscle bleeding or haematoma	30 – 60	Repeat infusion every 12 - 24 hours for 3 - 4 days or more until pain and acute disability are resolved.
Life threatening haemorrhages	60 – 100	Repeat infusion every 8 to 24 hours until threat is resolved
<u>Surgery</u>		
Minor surgery including tooth extraction	30 – 60	Every 24 hours, at least 1 day, until healing is achieved.
Major surgery	80 - 100 (pre- and post-operative)	Repeat infusion every 8 - 24 hours until adequate wound healing, then therapy for at least another 7 days to maintain a factor VIII activity of 30% to 60% (IU/dL).

### *Prophylaxis*

For long term prophylaxis against bleeding in patients with severe haemophilia A, the usual doses for adolescents ( $\geq 12$  years age) and adult patients are 20 to 40 IU of Kovaltry per kg body weight two to three times per week.

In some cases, especially in younger patients, shorter dose intervals or higher doses may be necessary.

### *Paediatric population*

A safety and efficacy study has been performed in children of 0-12 years (see section 5.1); The recommended prophylaxis doses are 20-50 IU/kg twice weekly, three times weekly or every other day according to individual requirements. For paediatric patients above the age of 12, the dose recommendations are the same as for adults.

### Method of administration

Intravenous use.

Kovaltry should be injected intravenously over 2 to 5 minutes depending on the total volume. The rate of administration should be determined by the patient's comfort level (maximal rate of infusion: 2 mL/min).

For instructions on reconstitution of the medicinal product before administration, see section 6.6 and the package leaflet.

### **4.3 Contraindications**

- Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
- Known allergic reactions to mouse or hamster proteins.

#### **4.4 Special warnings and precautions for use**

##### Traceability

In order to improve traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.

##### Hypersensitivity

Allergic type hypersensitivity reactions are possible with Kovaltry.

If symptoms of hypersensitivity occur, patients should be advised to discontinue the use of the medicinal product immediately and contact their physician.

Patients should be informed of the early signs of hypersensitivity reactions including hives, , generalised urticaria, tightness of the chest, wheezing, hypotension, and anaphylaxis.

In case of shock, standard medical treatment for shock should be implemented.

##### Inhibitors

The formation of neutralising antibodies (inhibitors) to factor VIII is a known complication in the management of individuals with haemophilia A. These inhibitors are usually IgG immunoglobulins directed against the factor VIII procoagulant activity, which are quantified in Bethesda Units (BU) per mL of plasma using the modified assay. The risk of developing inhibitors is correlated to the severity of the disease as well as the exposure to factor VIII, this risk being highest within the first 50 exposure days. but continues throughout life although the risk is uncommon.

The clinical relevance of inhibitor development will depend on the titre of the inhibitor, with low titre posing less of a risk of insufficient clinical response than high titre inhibitors.

In general, all patients treated with coagulation factor VIII products should be carefully monitored for the development of inhibitors by appropriate clinical observations and laboratory tests (see section 4.2).

If the expected factor VIII activity plasma levels are not attained, or if bleeding is not controlled with an appropriate dose, testing for factor VIII inhibitor presence should be performed. In patients with high levels of inhibitor, factor VIII therapy may not be effective and other therapeutic options should be considered. Management of such patients should be directed by physicians with experience in the care of haemophilia and factor VIII inhibitors.

##### Cardiovascular events

In patients with existing cardiovascular risk factors, substitution therapy with FVIII may increase the cardiovascular risk

##### Catheter-related complications

If a central venous access device (CVAD) is required, risk of CVAD-related complications including local infections, bacteraemia and catheter site thrombosis should be considered.

It is strongly recommended that every time that Kovaltry is administered to a patient, the name and batch number of the product are recorded in order to maintain a link between the patient and the batch of the medicinal product.

##### Paediatric population

The listed warnings and precautions apply both to adults and children.

## Sodium content

This medicinal product contains less than 1 mmol sodium (23 mg) per dose, i.e. essentially 'sodium-free'.

### **4.5 Interactions with other medicinal products and other forms of interaction**

No interactions of human coagulation factor VIII (rDNA) products with other medicinal products have been reported.

### **4.6 Fertility, pregnancy and lactation**

#### Pregnancy

Animal reproduction studies have not been conducted with factor VIII. Based on the rare occurrence of haemophilia A in women, experience regarding the use of factor VIII during pregnancy is not available.

Therefore, factor VIII should be used during pregnancy only if clearly indicated.

#### Breast feeding

It is unknown whether Kovaltry is excreted in human milk. The excretion in animals has not been studied. Therefore, factor VIII should be used during breast-feeding only if clearly indicated.

#### Fertility

No animal fertility studies have been conducted with Kovaltry and its effect on human fertility has not been established in controlled clinical trials. Since Kovaltry is a replacement protein of endogenous factor VIII, no adverse effects on fertility are expected.

### **4.7 Effects on ability to drive or use machines**

If patients experience dizziness or other symptoms affecting their ability to concentrate and react, it is recommended that they do not drive or use machines until the reaction subsides.

### **4.8 Undesirable effects**

#### Summary of the safety profile

Hypersensitivity or allergic reactions (which may include angioedema, burning and stinging at the infusion site, chills, flushing, generalised urticaria, headache, hives, hypotension, lethargy, nausea, restlessness, tachycardia, tightness of the chest, tingling, vomiting, wheezing) have been observed and may in some cases progress to severe anaphylaxis (including shock).

Development of antibodies to mouse and hamster protein with related hypersensitivity reactions may occur.

Development of neutralising antibodies (inhibitors) may occur in patients with haemophilia A treated with factor VIII, including with Kovaltry. If such inhibitors occur, the condition may manifest itself as an insufficient clinical response. In such cases, it is recommended that a specialised haemophilia centre be contacted.

Tabulated list of adverse reactions

The table presented below is according to the MedDRA system organ classification (SOC and Preferred Term Level). Frequencies have been evaluated according to the following convention: very common ( $\geq 1/10$ ), common ( $\geq 1/100$  to  $< 1/10$ ), uncommon ( $\geq 1/1,000$  to  $< 1/100$ ), rare ( $\geq 1/10,000$  to  $< 1/1,000$ ); very rare ( $< 1/10,000$ ).

Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.

**Table 2: Frequency of adverse drug reactions in clinical trials**

MedDRA System Organ Class	Adverse reactions	Frequency
<b>Blood and lymphatic system disorders</b>	Lymphadenopathy	uncommon
	FVIII inhibitor	very common (PUPs)* uncommon (PTPs)*
<b>Immune system disorders</b>	Hypersensitivity	uncommon
<b>Psychiatric disorders</b>	Insomnia	common
<b>Nervous system disorders</b>	Headache,	common
	Dizziness	common
	Dysgeusia	uncommon
<b>Cardiac disorders</b>	Palpitation,	uncommon
	Sinus tachycardia	uncommon
<b>Vascular disorders</b>	Flushing	uncommon
<b>Gastrointestinal disorders</b>	Abdominal pain,	common
	Abdominal discomfort	common
	Dyspepsia	common
<b>Skin and subcutaneous tissue disorders</b>	Pruritus,	common
	Rash***,	common
	Urticaria	common
	Dermatitis allergic	uncommon
<b>General disorders and administration site conditions</b>	Pyrexia,	Common
	injection site reactions **	common
	Chest discomfort	uncommon

\* Frequency is based on studies with all FVIII products which included patients with severe haemophilia A. PTPs = previously-treated patients, PUPs = previously-untreated patients

\*\*includes injection site extravasation, hematoma, infusion site pain, pruritus, swelling

\*\*\* rash, rash erythematous, rash pruritic, rash vesicular

Description of selected adverse reactions

A total of 236 (193 PTPs, 43 PUPs/MTPs) patients constituted the pooled safety population in the three phase III studies in previously treated patients (PTPs), previously untreated patients (PUPs) and

minimal treated patients (MTPs); LEOPOLD I, LEOPOLD II, LEOPOLD Kids studies. The median time on clinical trial for pooled safety population was 558 days (range 14 to 2436 days) with a median of 183 exposure days (EDs) (range 1 to 1230 EDs).

- The most frequently reported adverse reactions in the pooled population were pyrexia, headache and, rash.
- The most frequently reported adverse reactions in the PTPs were related to potential hypersensitivity reactions, including headache, pyrexia, pruritus, rash and abdominal discomfort.
- The most frequently reported adverse reaction in PUPs/MTPs was FVIII inhibitor.

#### *Immunogenicity*

The immunogenicity of Kovaltry was evaluated in PTPs and PUPs/MTPs.

During clinical trials with Kovaltry in approximately 200 pediatric and adult patients diagnosed with severe hemophilia A (FVIII:C < 1%) with previous exposure to factor VIII concentrates  $\geq$  50 ED, one case of transient low titer inhibitor (peak titer 1.0 BU/mL) occurred in a 13 year old PTP after 549 EDs. The Factor VIII recovery was normal (2.7 IU/dL per IU/kg).

#### *Paediatric population*

In the clinical studies no age-specific differences in ADR were observed except for FVIII inhibitor in PUPs/MTPs.

#### Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.

Any suspected adverse events should be reported to the Ministry of Health according to the National Regulation by using an online form

<https://sideeffects.health.gov.il/>

#### **4.9 Overdose**

No symptoms of overdose with recombinant human coagulation factor VIII have been reported.

## **5. PHARMACOLOGICAL PROPERTIES**

### **5.1 Pharmacodynamic properties**

Pharmacotherapeutic group: antihemorrhagics: blood coagulation factor VIII, ATC code B02BD02.

## Mechanism of action

The factor VIII/von Willebrand factor (vWF) complex consists of two molecules (factor VIII and vWF) with different physiological functions. When infused into a haemophiliac patient, factor VIII binds to vWF in the patient's circulation. Activated factor VIII acts as a cofactor for activated factor IX, accelerating the conversion of factor X to activated factor X. Activated factor X converts prothrombin into thrombin. Thrombin then converts fibrinogen into fibrin and a clot can be formed. Haemophilia A is a sex-linked hereditary disorder of blood coagulation due to decreased levels of factor VIII:C and results in profuse bleeding into joints, muscles or internal organs, either spontaneously or as a result of accidental or surgical trauma. By replacement therapy the plasma levels of factor VIII are increased, thereby enabling a temporary correction of the factor deficiency and correction of the bleeding tendencies.

Of note, annualized bleeding rate (ABR) is not comparable between different factor concentrates and between different clinical studies.

Kovaltry does not contain von Willebrand factor.

## Pharmacodynamic effects

The activated partial thromboplastin time (aPTT) is prolonged in people with haemophilia. Determination of aPTT is a conventional *in vitro* assay for biological activity of factor VIII. Treatment with rFVIII normalizes the aPTT similar to that achieved with plasma-derived factor VIII.

## Clinical efficacy and safety

### *Control and Prevention of Bleeding*

Two multi-centre, open-label, cross-over, uncontrolled, randomized studies in previously treated adults/adolescents with severe haemophilia A (< 1%) and one multicentre, open label, uncontrolled study in PTPs < 12 years of age (Part A) and PUPs/MTPs < 6 years of age (Part B) with severe haemophilia A were conducted.

A total of 247 subjects (204 PTPs and 43 PUPs/MTPs) have been exposed in the clinical trial program, 153 subjects  $\geq$  12 years and 94 subjects < 12 years. Two-hundred and eight (208) subjects (174 PTPs, 34 PUPs/MTPs) were treated for at least 360 days, and 98 of these subjects (78 PTPs, 20 PUPs/MTPs) for at least 720 days.

### *Paediatric population <12 years*

**Part A:** The paediatric trial enrolled 51 PTPs with severe haemophilia A, 26 subjects in the age group 6-12 years and 25 subjects in the age group < 6 years having accumulated a median number of 73 EDs (range: 37 to 103 EDs). Subjects were treated with 2 or 3 injections per week or up to every other day at a dose of 25 to 50 IU/kg. Consumption for prophylaxis and treatment of bleeds, annualised bleed rates and success rate for bleed treatment are presented in Table 3.

**Part B:** A total of 43 PUPs/MTPs were enrolled and accumulated a median of 46 EDs (range 1 to 55 EDs). The median dose for treatment of bleeds in all PUPs/MTPs was 40.5 IU/kg and 78.1% of the bleeds were successfully treated with  $\leq$  2 infusions.

The most frequently reported adverse reaction in PUPs/MTPs was Factor VIII inhibitor (see section 4.8). FVIII inhibitors were detected in 23 of 42 patients with a median (range) of 9 (4 – 42) EDs at the time of the first positive inhibitor test. Of these, 6 patients had low-titre inhibitors ( $\leq$  5.0 BU) and 17 patients had high-titre inhibitors.

**Extension:** Of the 94 treated subjects, 82 subjects entered the Leopold Kids extension study, 79 patients received treatment with Kovaltry and 67 patients received Kovaltry as prophylaxis treatment. The median time in the extension study was 3.1 years (range 0.3 to 6.4 years), the median total time in entire study (main plus extension study) was 3.8 years (range 0.8 to 6.7 years).



During the extension study, 67 of 82 subjects received Kovaltry as prophylaxis treatment. Amongst the 67 subjects, a total of 472 bleeds were treated with Kovaltry, requiring 1-2 infusions for the majority of bleeds (83.5%), and response to treatment was good or excellent in most (87.9%) of the cases.

#### *Immune Tolerance Induction (ITI)*

Data on ITI has been collected in patients with haemophilia A. 11 subjects with high titer inhibitors received ITI with various treatment regimens of three times per week up to twice daily. 5 subjects completed ITI with a negative inhibitor result at the end of the study, and 1 subject had a low titer (1.2 BU/mL) at time of discontinuation.

**Table 3: Consumption and overall success rates (patients treated with prophylaxis only)**

	Younger children (0 <6 years)	Older children (6 <12 years)	Adolescents and adults 12-65 years			Total
			Study 1	Study 2 2 x/week dosing	Study 2 3 x/week dosing	
<b>Study participants</b>	25	26	62	28	31	172
<b>Dose/prophylaxis injection, IU/kg BW median (min, max)</b>	36 IU/kg (21; 58 IU/kg)	32 IU/kg (22; 50 IU/kg)	31 IU/kg (21; 43 IU/kg)	30 IU/kg (21; 34 IU/kg)	37 IU/kg (30; 42 IU/kg)	32 IU/kg (21; 58 IU/kg)
<b>ABR – all bleeds (median, Q1,Q3)</b>	2.0 (0.0; 6.0)	0.9 (0.0; 5.8)	1.0 (0.0; 5.1)	4.0 (0.0; 8.0)	2.0 (0.0; 4.9)	2.0 (0.0; 6.1)
<b>Dose/injection for bleed treatment Median (min; max)</b>	39 IU/kg (21;72 IU /kg)	32 IU/kg (22; 50 IU/kg)	29 IU/kg (13; 54 IU/kg)	28 IU/kg (19; 39 IU/kg)	31 IU/kg (21; 49 IU/kg)	31 IU/kg (13; 72 IU/kg)
<b>Success rate*</b>	92.4%	86.7%	86.3%	95.0%	97.7%	91.4%

ABR annualized bleed rate

Q1 first quartile; Q3 third quartile

BW: Body weight

\*Success rate defined as % of bleeds treated successfully with  $\leq 2$  infusions

## **5.2 Pharmacokinetic properties**

The pharmacokinetic (PK) profile of Kovaltry was evaluated in PTPs with severe haemophilia A following 50 IU/kg in 21 subjects  $\geq 18$  years, 5 subjects  $\geq 12$  years and  $< 18$  years and 19 subjects  $< 12$  years of age.

A population PK model was developed based on all available FVIII measurements (from dense PK sampling and all recovery samples) throughout the 3 clinical studies allowing calculation of PK

parameters for subjects in the various studies. The table 4 below provides PK parameters based on the population PK model.

**Table 4: PK parameters (geometric mean (%CV)) based on chromogenic assay. \***

PK parameter	≥ 18 years N=109	12-<18 years N=23	6-<12 years N=27	0-<6 years N=24
T <sub>1/2</sub> (h)	14.8 (34)	13.3 (24)	14.1 (31)	13.3 (24)
AUC (IU.h/dL)**	1,858 (38)	1,523 (27)	1,242 (35)	970 (25)
CL (dL/h/kg)	0.03 (38)	0.03 (27)	0.04 (35)	0.05 (25)
V <sub>ss</sub> (dL/kg)	0.56 (14)	0.61 (14)	0.77 (15)	0.92 (11)

\* Based on population PK estimates

\*\*AUC calculated for a dose of 50 IU/kg

Repeated PK measurements after 6 to 12 months of prophylaxis treatment with Kovaltry did not indicate any relevant changes in PK characteristics after long-term treatment.

In an international study involving 41 clinical laboratories, the performance of Kovaltry in FVIII:C assays was evaluated and compared to a marketed full length rFVIII product. Consistent results were determined for both products. The FVIII:C of Kovaltry can be measured in plasma with a one-stage coagulation assay as well as with a chromogenic assay using the routine methods of the laboratory.

The analysis of all recorded *incremental* recoveries in previously treated patients demonstrated a median rise of > 2% (> 2 IU/dL) per IU/kg body weight for Kovaltry. This result is similar to the reported values for factor VIII derived from human plasma. There was no relevant change over the 6-12 months treatment period.

**Table 5: Phase III incremental recovery results**

Study participants	N=115
Chromogenic assay results Median; (Q1; Q3) (IU/dL / IU/kg)	2.3 (1.8; 2.6)
One-stage assay results Median; (Q1; Q3) (IU/dL / IU/kg)	2.2 (1.8; 2.4)

### 5.3 Preclinical safety data

Non-clinical data reveal no special risk for humans based on safety pharmacology, *in vitro* genotoxicity, and short term repeat-dose toxicity studies. Repeat-dose toxicity studies longer than 5 days, reproductive toxicity studies, and carcinogenicity studies, have not been performed. Such studies are not considered meaningful due to the production of antibodies against the heterologous human protein in animals. Also FVIII is an intrinsic protein and not known to cause any reproductive or carcinogenic effects.

## 6. PHARMACEUTICAL PARTICULARS

### 6.1 List of excipients

#### Powder

Glycine

Sucrose

Histidine

Sodium chloride

Calcium chloride dihydrate

Polysorbate 80

Acetic acid, glacial (for pH adjustment)

## Solvent

Water for injections

### **6.2 Incompatibilities**

In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.

Only the provided infusion sets should be used for reconstitution and injection because treatment failure can occur as a consequence of human recombinant coagulation factor VIII adsorption to the internal surfaces of some infusion equipment.

### **6.3 Shelf-life**

The expiry date of the product is indicated on the packaging materials.

The chemical and physical in-use stability after reconstitution has been demonstrated for 3 hours at room temperature.

After reconstitution, from a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user.

Do not refrigerate after reconstitution.

### **6.4 Special precautions for storage**

Store in a refrigerator (2 °C - 8 °C).

Do not freeze.

Keep the vial and the pre-filled syringe in the outer carton in order to protect from light.

Within its overall shelf life of 30 months the product when kept in its outer carton, may be stored up to 25 °C for a limited period of 12 months. In this case, the product expires at the end of this 12-month period or the expiry date on the product vial, whichever is earlier. The new expiry date must be noted on the outer carton.

For storage conditions after reconstitution of the medicinal product, see section 6.3.

### **6.5 Nature and contents of container and special equipment for use, administration or implantation**

Each package of Kovaltry contains:

- one vial with powder (10 mL clear glass type 1 vial with grey halogenobutyl rubber blend stopper and aluminium seal)
- one pre-filled syringe with 2.5 mL (for 250 IU, 500 IU and 1000 IU) or 5 mL (for 2000 IU) solvent (clear glass cylinder type 1 with grey bromobutyl rubber blend stopper)
- syringe plunger rod
- vial adapter
- one venipuncture set

### **6.6 Special precautions for disposal and other handling**

Detailed instructions for preparation and administration are contained in the package leaflet provided with Kovaltry.

The reconstituted medicinal product is a clear and colourless solution.

Kovaltry powder should only be reconstituted with the supplied solvent (2.5 mL or 5 mL water for injections) in the prefilled syringe and the vial adapter. For infusion, the product must be prepared

under aseptic conditions. If any component of the package is opened or damaged, do not use this component.

After reconstitution the solution is clear. Parenteral medicinal products should be inspected visually for particulate matter and discoloration prior to administration. Do not use Kovaltry if you notice visible particulate matter or turbidity.

After reconstitution, the solution is drawn back into the syringe. Kovaltry should be reconstituted and administered with the components (vial adapter, prefilled syringe, venipuncture set) provided with each package.

The reconstituted product must be filtered prior to administration to remove potential particulate matter in the solution. Filtering is achieved by using the vial adapter.

The venipuncture set provided with the product must not be used for drawing blood because it contains an in-line filter.

For single use only.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

## **7. MANUFACTURER**

Bayer AG, Leverkusen, Germany

## **8. REGISTRATION HOLDER**

Bayer Israel Ltd., 36 Hacharash St., Hod Hasharon 45240.

Revised in October 2022 according to MoH guidelines

